Pacira BioSciences, Inc. PCRX Accrued research and development expenses

Other financials

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Market cap$942.78M-14.5%

Enterprise value$1.21B+2.6%

P/E183.5×—

P/S1.3×-0.3×

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept pcrx:AccruedResearchAndDevelopmentExpenses.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Pacira BioSciences, Inc.'s accrued research and development expenses?: Pacira BioSciences, Inc. (PCRX) reported accrued research and development expenses of $7.95M in Q1 2026.